Recro Pharma (NASDAQ:REPH) Earns Overweight Rating from Analysts at Stephens

Stephens began coverage on shares of Recro Pharma (NASDAQ:REPH) in a report released on Wednesday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $14.00 price objective on the specialty pharmaceutical company’s stock.

Several other research analysts have also weighed in on REPH. BidaskClub upgraded Recro Pharma from a buy rating to a strong-buy rating in a report on Tuesday, October 8th. Oppenheimer set a $20.00 target price on Recro Pharma and gave the stock a buy rating in a report on Friday, August 9th. ValuEngine lowered Recro Pharma from a buy rating to a hold rating in a report on Tuesday, October 1st. Finally, Zacks Investment Research lowered Recro Pharma from a strong-buy rating to a hold rating in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Recro Pharma currently has a consensus rating of Buy and a consensus target price of $12.92.

Shares of Recro Pharma stock traded up $0.06 during trading on Wednesday, reaching $12.18. 83,670 shares of the company were exchanged, compared to its average volume of 171,729. The business has a 50-day moving average price of $11.62 and a 200-day moving average price of $10.05. The firm has a market capitalization of $271.82 million, a price-to-earnings ratio of -4.89 and a beta of -0.50. Recro Pharma has a twelve month low of $5.53 and a twelve month high of $12.67.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. The business had revenue of $31.26 million for the quarter, compared to the consensus estimate of $24.06 million. On average, analysts expect that Recro Pharma will post -0.48 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of REPH. Campbell & CO Investment Adviser LLC bought a new position in Recro Pharma during the second quarter worth about $397,000. Bessemer Group Inc. bought a new stake in shares of Recro Pharma in the second quarter valued at about $57,000. Dupont Capital Management Corp bought a new stake in shares of Recro Pharma in the second quarter valued at about $563,000. Wedge Capital Management L L P NC bought a new stake in shares of Recro Pharma in the second quarter valued at about $1,682,000. Finally, Chicago Equity Partners LLC bought a new stake in shares of Recro Pharma in the second quarter valued at about $576,000. Hedge funds and other institutional investors own 60.50% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: How does a security become overbought?

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.